SEARCH

SEARCH BY CITATION

References

  • 1
    Abel-Smith B, Figueras J, Holland W, McKee M, Mossialos E. Choices in Health Policy. an Agenda for the European Union. Office For Official Publications of the European Communities, Luxembourg. Cambridge: Darmouth Publishing Co, Ltd, University Press, 1995, pp. 1163.
  • 2
    Taylor D. Prescribing in Europe – forces for change. Br Med J 1992; 304: 239242.
  • 3
    Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. I. Influencing patients. Br Med J 1996; 312: 14691471.
  • 4
    Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. II. Influencing doctors. Br Med J 1996; 312: 15251527.
  • 5
    Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. III. Regulating industry. Br Med J 1996; 313: 3335.
  • 6
    Abel-Smith B, Mossialos E. Cost containment and health care reform. a study of the European Union. Health Policy 1994; 28: 89132.
  • 7
    Ray AW, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993; 329: 20292032.
  • 8
    Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 16041609.
  • 9
    Cochrane Collaboration. In The Cochrane Library, Issue 4. Oxford: Update Software.
  • 10
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment, 3rd edn. Oslo, 2000.
  • 11
    Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Clin Pharmacol 1996; 50: 2730.
  • 12
    IMS Health. IMS MIDAS 1998. PA: IMS Health, Plymouth Meeting, 1998.
  • 13
    Läkemedelsstatistik AB Sweden, 1998.
  • 14
    Montagne O, Vedel I, Durand-Zaleski I. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomised, controlled trials in coronary heart disease and health economic evaluations. Clin Ther 1999; 12: 20272035.
  • 15
    Report of the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Lancet 1984; ii: 600604.
  • 16
    Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Torri V, Liberati A. Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice? Arch Ophthalmol 1993, 2000; 111: 96103.
  • 17
    López-Arrieta Birks J. Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). In The Cochrane Library, Issue 1. Oxford: Update Software, 2000.
  • 18
    Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment (Cochrane Review). In The Cochrane Library, Issue 1. Oxford: Update Software, 2000.
  • 19
    Poole PJ, Black PN. Mucolytic agents for chronic bronchitis (Cochrane Review). In The Cochrane Library, Issue 1. Oxford: Update Software, 2000.
  • 20
    Meunier PJ. Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Int J Clin Pract 1999; 53: 122129.
  • 21
    Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis (Cochrane Review). In The Cochrane Library, Issue 1. Oxford: Update Software, 2000.
  • 22
    Kumana CR, Ching TY, Cheung E, et al. Antiulcer drug prescribing in hospital successfully influenced by ‘immediate concurrent feedback’. Clin Pharmacol Ther 1998; 64: 569574.
  • 23
    Siminoski K, Josse RG. Prevention and management of osteoporosis. Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis. CMAJ 1996; 155: 962965.
  • 24
    Veninga CC, Lagerlov P, Wahlstrom R, et al. Evaluating an educational intervention to improve the treatment of asthma in four European countries. Drug Education Project Group. Am J Respir Crit Care Med 1999; 160: 12541262.
  • 25
    Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near-death from asthma. N Engl J Med 1992; 326: 501506.
  • 26
    Van Rijkom JEF, Leufkens HGM, Crommelin DJA, Rutten FFH, Broekmans AW. Assessment of biotechnology drugs: what are the issues? Health Policy 1999; 47: 255274.
  • 27
    Payer L. Medicine and Culture. New York: Henry Holt and Co., 1988.
  • 28
    Etzioni A, Remp R. Technological ‘short-cuts’ to social change. Science 1972; 175: 3138.
  • 29
    Rudolf M. The reality of drug use in COPD. the European perspective. Chest 2000; 117 (2 Suppl): 29S32S.
  • 30
    Dukes MNG, ed. Drug Utilization Studies. Methods and Uses, European Series no. 45. WHO Regional Publications, 1993.
  • 31
    Garattini S, Garattini L. Pharmaceutical prescriptions in four European countries. Lancet 1993; 342: 11911192.
  • 32
    Soumerai SB, Ross Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q 1993; 71: 217252.
  • 33
    Leufkens HG, Haaijer-Ruskamp F, Bakker A, Dukes G. Scenario analysis of the future of medicines. Br Med J 1994; 309: 11371140.